Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer (CaP)

Description

This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with advanced prostate cancer.

Conditions

Advanced Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with advanced prostate cancer.

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer (CaP)

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer (CaP)

Condition
Advanced Prostate Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Jacksonville

Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224-9980

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * GROUP 1 FOCUS GROUPS:
  • * Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
  • * Are 18 years of age or older
  • * Have histologic evidence of prostate adenocarcinoma
  • * Are requiring prostate cancer therapy
  • * Have an understanding of the protocol and its requirements
  • * Are willing to fill in a questionnaire and participate in a focused interview
  • * Are able and willing to sign an informed consent
  • * Enrollment in the survey phase of the protocol
  • * Are 18 years of age or older
  • * Have histologic evidence of prostate adenocarcinoma
  • * Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
  • * Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of advanced care at home program (ACH)
  • * Have an understanding of the protocol and its requirements
  • * Are able and willing to sign an informed consent
  • * GROUP 1 FOCUS GROUPS:
  • * Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
  • * Do not identify as Black men
  • * Have not been diagnosed with advanced/metastatic CaP
  • * Are not requiring active standard anti-cancer therapy
  • * Not enrolled in the survey phase of the protocol
  • * Do not identify as Black men
  • * Have not been diagnosed with advanced/metastatic CaP
  • * Are not requiring active standard anti-cancer therapy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Mayo Clinic,

Roxana S. Dronca, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2026-07-30